Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL BCP 2020 for childhood relapsed precursor B-cell ALL
NL-OMON60511Phase 3Not yet recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin and blinatumomab in acute lymphoblastic leukemia (ALL) (5 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Event-free survival in standard-risk induction, Disease-free survival in standard-risk MRD good response consolidation and 2 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicinblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON60511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60511.